View Older Stories View More Recent Stories
-
AstraZeneca (AZN): AIRSUPRA demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma
-
AstraZeneca (AZN) reports Airsupra demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthm
-
AstraZeneca (AZN) entres license agreement for a pre-clinical novel lipid-lowering therapy
-
AstraZeneca (AZN): CALQUENCE granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
AstraZeneca (AZN) reports Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
-
Arcus Biosciences (RCUS) Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
-
AstraZeneca (AZN): ENHERTU granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer
-
AstraZeneca's (AZN) ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
-
Erste Group Downgrades AstraZeneca (AZN) to Hold
-
AstraZeneca (AZN): TAGRISSO approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
-
AstraZeneca (AZN) announces Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
-
Barclays on Gilead Sciences (GILD): 'Modest positive read-through for Trodelvy positioning in 2L+ HR/Her2- breast cancer'
-
AstraZeneca (AZN)
-
AstraZeneca (AZN) announces FluMist approved for self-administration in the US
-
AstraZeneca (AZN): FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
-
AstraZeneca's (AZN) Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
-
AstraZeneca (AZN): IMFINZI plus IMJUDO demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
-
AstraZeneca (AZN) reports Imfinzi plus Imjudo demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
-
AstraZeneca (AZN) Reports ENHERTU showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
-
Deutsche Bank Downgrades AstraZeneca (AZN:LN) (AZN) to Sell
-
BioInvent Announces the Enrollment of the First Patient in Triple Combination Arm of BI-1206, Rituximab and Calquence(R) for the Treatment of non-Hodgkin's Lymphoma
-
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
-
Erste Group Upgrades AstraZeneca (AZN) to Buy
-
SOPHiA GENETICS (SOPH) and AstraZeneca (AZN) Partner to Further Expand Global Access to Liquid Biopsy Testing
-
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN), PT $91.70, 'TL-01 final OS underwhelms', Shares down ~2.3%
-
AstraZeneca (AZN) Shares Down 3%+ Following Update
-
AstraZeneca (AZN) Shares Down ~2.5% Following Update
-
AstraZeneca (AZN) reports datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
-
AstraZeneca (AZN) completes clinical programme to support the transition of Breztri to next-generation propellant with near-zero Global Warming Potential
-
China Detains AstraZeneca (AZN) Staff in Data, Drug-import Probes - Bloomberg
-
AstraZeneca (AZN) advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
-
AstraZeneca's (AZN) IMFINZI approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
-
AstraZeneca’s (AZN) IMFINZI Granted FDA Priority Review and Breakthrough Therapy Designation
-
AstraZeneca (AZN): Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
-
AstraZeneca (AZN) PT Raised to $95 at TD Cowen
-
AstraZeneca (AZN): Fixed-duration CALQUENCE plus venetoclax, with or without obinutuzumab, significantly improved PFS in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
-
AstraZeneca (AZN) reports FDA AdCom reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results
-
AstraZeneca (AZN) Tops Q2 EPS by 99c; offers guidance
-
AstraZeneca (AZN) July weekly 79 straddle priced into quarter results
-
AstraZeneca (AZN) Completes Acquisition of Amolyt Pharma
-
Morgan Stanley Reiterates Overweight Rating on AstraZeneca (AZN:LN) (AZN)
-
Morgan Stanley is out with its 'Top Stock Picks' list for Europe
-
AstraZeneca's (AZN) Tagrisso plus chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
AstraZeneca (AZN) reports Lynparza plus Imfinzi recommended for approval in the EU by CHMP
-
AstraZeneca's (AZN) Tagrisso plus chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
AstraZeneca (AZN): IMFINZI demonstrated statistically significant and clinically meaningful improvement in EFS and OS for muscle-invasive bladder cancer in NIAGARA Phase III trial
-
AstraZeneca (AZN) reports Imfinzi showed statistically significant improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
-
AstraZeneca (AZN) Issues Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer
-
AstraZeneca (AZN) reports Tagrisso plus chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
-
AstraZeneca (AZN) announces Truqap plus Faslodex approved in the EU
